Advertisement

Topics

NICE U-turn on Adcetris disappoints because of added restriction, says Takeda

11:10 EDT 24 Aug 2017 | thePharmaLetter

In a final appraisal, UK cost-effectiveness watchdog the National Institute for Health and Care Excellence…

Original Article: NICE U-turn on Adcetris disappoints because of added restriction, says Takeda

NEXT ARTICLE

More From BioPortfolio on "NICE U-turn on Adcetris disappoints because of added restriction, says Takeda"

Advertisement
Quick Search
Advertisement
Advertisement